CD19 and rheumatoid arthritis: As expected, the peripheral blood level of CD19+ cells were elevated in RA patients not on abatacept compared to the healthy controls (Supplementary Fig. 2B; P = 0.0044); while treatment with abatacept dramatically reduced their levels (Supplementary Fig. 2B; P = 0.0169).